Skip to main content


Featured article: Use of uracil-DNA glycosylase enzyme to reduce DNA-related artifacts

This research by Berra et al., published in the BMC cross-journal Precision Oncology thematic series, aimed to evaluate the effects of uracil DNA glycosylase enzymatic pretreatment in reducing the number of DNA sequencing artifacts from formalin-fixed and paraffin-embedded tumor samples, to improve the accuracy of genetic testing in the molecular diagnostic routine.

Aims and scope

Applied Cancer Research is an open access, peer-reviewed journal focused on clinical, surgical and translational research in the field of oncology. The journal considers for publication original articles addressing genetics, pathology, immuno-oncology, microbiome, bioinformatics, diagnosis, treatment, patient care, and population sciences of cancer. Read more.


Most accessed articles RSS

View all articles

Archival content

Applied Cancer Research, formerly Acta Oncológica Brasileira, was founded in 1975 and transferred to BioMed Central in 2016. An electronic archive of articles published until 2015 can be found here.

Free to publish for limited time

The publication costs for Applied Cancer Research are currently covered by the A.C.Camargo Cancer Center and therefore no fees for article processing will be charged to authors whose articles are accepted for publication. 

Institutional affiliation

Founded in Sao Paulo in 1953, A.C.Camargo Cancer Center is an international reference center in oncology, with over 5,000 employees, in addition to 700 doctors and multidisciplinary specialists, 270 residents and 238 students enrolled in our master's and PhD courses. For more info, please visit the institution's website.

Sign up to receive article alerts

Applied Cancer Research is published continuously online-only. We encourage you to sign up to receive free email alerts to keep up to date with all of the latest articles by registering here.

Latest Tweets

About the Editor-in-Chief

Kenneth Gollob graduated with a PhD from the University of Colorado Health Sciences Center/National Jewish Center for Immunology in 1991. His postdoctoral training was performed at DNAX Research Institute in Palo Alto, CA, and he has held positions as Visiting Associate Professor and Visiting Scientist at Stanford University School of Medicine and the Centers for Disease Control. Currently he is Head of the Translational Immuno-oncology Group at A.C. Camargo Cancer Center in São Paulo, Brazil.  His work focuses on defining immune mechanisms and biomarkers of disease progression, adverse event development, and response to standard and immunotherapy of cancer. 


Annual Journal Metrics

  • Speed
    57 days to first decision for reviewed manuscripts only
    46 days to first decision for all manuscripts
    101 days from submission to acceptance
    24 days from acceptance to publication

    21 Altmetric Mentions